Aflac is expanding its partnership with Empathy to provide the LifeVault service at no additional cost to certain group term life insurance certificate holders, effective July 1, 2025. During the past month, Aflac's share price moved by 3.8%, an increase that likely adds weight to broader market trends, as the Dow Jones Industrial Average and S&P 500 rose modestly amid other mixed stock activities. Aflac's recent partnership announcement and dividend declaration of $0.58 per share provide a positive backdrop, though the company's first-quarter earnings reported significant declines in net income and earnings per share.

We've identified 1 weakness with Aflac and understanding the impact should be part of your investment process.NYSE:AFL Revenue & Expenses Breakdown as at May 2025

We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

The recent partnership between Aflac and Empathy, along with the dividend declaration, could bolster investor confidence despite the challenges highlighted. Over the past five years, Aflac's total shareholder return was a very large 255.63%, including dividends, underscoring its long-term performance strength. For context, Aflac's stock price has done better than both the US market and Insurance industry over the past year, despite a notable 32.8% decline in earnings, surpassing the broader US market's 8.2% return and the US Insurance industry's 17.1% return. This suggests resilience even amid current headwinds.

In terms of potential business impacts, the partnership aims to enhance Aflac’s product offerings, which might support future revenue and earnings forecasts by addressing segment challenges, particularly in the U.S. dental and vision markets. However, external factors like yen-dollar volatility and commercial real estate uncertainty could still pose risks to revenue and credit quality. Currently, Aflac's share price of US$108.60 is about 2.9% above the analysts' consensus price target of US$105.54, suggesting the market might already be pricing in some of the expected future growth and risks enumerated by analysts.

The valuation report we've compiled suggests that Aflac's current price could be inflated.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Story Continues

Companies discussed in this article include NYSE:AFL.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments